Skip to main content
Premium Trial:

Request an Annual Quote

Seegene, Selventa Partner on MDx Development for 'Underserved Markets'

NEW YORK (GenomeWeb News) – Seegene and Selventa have entered into a collaborative agreement to develop molecular diagnostic products for "underserved markets" including autoimmune disease, cancer, and infectious diseases, the companies said today.

Under the partnership, the companies will combine Selventa's Systems Diagnostics "multi-omic analytics" platform with Seegene's qTOCE and DPO multiplex PCR chemistries to develop new molecular diagnostics.

Selventa's SysDx works by analyzing a range of molecular information — for example, genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical record information — from a patient to identify a panel of "multi-omic" biomarkers that can accurately diagnose a patient's disease and response or non-response to a therapy, the company said.

Seegene's quantitative TOCE (tagging oligonucleotide capture and extension) and DPO (dual priming oligonucleotide) technologies enable highly multiplexed assays based on real-time PCR. For instance, qTOCE provides real-time simultaneous detection and quantification of multiple targets in a single channel on any qPCR instrument to differentiate as many as seven targets per channel from a single sample, in a single reaction, according to the company.

Financial terms of the agreement were not disclosed.